A 27-year-old man was admitted to the emergency department with fever and thoracic pain.…
- User
A 27-year-old man was admitted to the emergency department with fever and thoracic pain. In the previous 6 months, the patient lost a substantial amount of weight (12 kg). His family history was negative for cardiac disease. Electrocardiography revealed sinus rhythm, and diffuse T-wave inversion. T wo-dimensional echocardiography was performed (Fig 1) and revealed normal left systolic function (ejection fraction, 60%). Laboratory tests showed elevated levels of high-sensitivity cardiac troponin (1.07 ng/mL; normal value, ,0.015 ng/mL), high levels of C-reactive protein (16 mg/dL; normal range, 0–5 mg/dL), and leukocytosis with an eosinophilia level of 8710/mL (normal level, ,400/mL). Parasitic and infectious diseases (T oxocara canis, strongyloides, filariasis, cysticercosis, fasciola, trichinella, echinococcosis) were excluded based on blood and fecal test results. Corticosteroid therapy was started, and the patient was dismissed. A few days later, he was readmitted to the emergency department with a headache and suddenly blurred vision. Neurologic and ophthalmologic findings were normal, and MRI of the brain was performed (Fig 2). Cardiac MRI (Fig 3) was performed 2 days later and revealed the following quantitative results: (a) left ventricular end-diastolic volume (LVDV) of 165 mL (LVDV/body surface area [BSA], 89 mL/m2; normal range, 64–100 mL/m2), left ventricular end-systolic volume (LVSV) of 80 mL (LVSV/BSA, 43 mL/m2; normal range, 17–39 mL/m2); stroke volume (SV) of 85 mL (SV/BSA, 46 mL/m2; normal range, 43–67 mL/m2); and ejection fraction of 52% and (b) right ventricular end-diastolic volume (RVDV) of 163 mL (RVDV/BSA, 88 mL/m2; normal range, 63–111 mL/ m2), right ventricular end-systolic volume (RVSV) of 81 mL (RVSV/BSA, 44 mL/m2; normal range, 32–92 mL/m2); stroke volume (SV) of 82 mL (SV/BSA, 44 mL/m2; normal range, 39–71 mL/m2); and ejection fraction of 50%.Two-dimensional transthoracic echocardiography four-chamber end-diastolic (Fig 1A) and end-systolic views showed left ventricle apical thickening (Fig 1B), demonstrating apical myocardial hypertrophy. Diffusion-weighted brain MRI showed small multiple ischemic subacute hyperintense lesions localized in the cortical and subcortical frontal and occipital lobes (Fig 2). Unenhanced three-chamber cine steady-state free precession cardiac MRI (Fig 3A) showed left ventricle apical obliteration by a large thrombus; it was also possible to recognize a very thin hyperintense layer separating the thrombus and myocardium. T riple inversion recovery three-chamber view (Fig 3B) showed massive and diffuse endocardial hyperintensity, showing diffuse endocardial edema. Short-axis cine steady-state free precession images acquired after gadoterate meglumine (0.4 mL/kg of body weight) administration showed thickening and hyperintensity of the endocardium in the end-diastolic (Fig 3C) and end-systolic (Fig 3D) phases, as well as expression of diffuse endocardial hyperemia, which was well visible as hypointensity of the endoventricular thrombotic deposition. Gradient-echo inversion recovery was performed 10 minutes after contrast media injection (late gadolinium enhancement technique), and two-chamber long- (Fig 3E) and short-axis (Fig 3F) images showed left ventricular apical thrombus and apical endocardial delayed enhancement. Note the “V sign” of endomyocardial fibrosis at the apex, characterized by a three-layered appearance of dark overlying thrombus, bright fibrotic endomyocardium, and dark underlying myocardium. In consideration of the cardiac MRI findings (endocardial thickening with diffuse edema or hyperemia and delayed enhancement, apical thrombus) and hypereosinophilia of 8.710 K/mL (normal , 0.4 K/ mL), Loeffler endocarditis was suspected. The patient underwent a bone marrow biopsy that showed numerous cellular aggregates of the bone marrow, with a prevalence of the eosinophilic granulocytic myeloid line, in various stages of maturation and with numerous immature forms, enabling us to confirm myeloidhypereosiniphilic syndrome. After chemotherapy with STI-571 (imatinib) and corticosteroid (25 mg) and heparin administration (eight units per kilogram of body weight per hour, intravenous drip), the patient had a rapid reduction of eosinophilia (1.0 K/mL) and improvement in physical condition, and, subsequently, 1 month later underwent follow-up cardiac MRI. Follow-up unenhanced cardiac short-axis threechamber view cine steady-state free precession MRI (Fig 4A) showed reduction of the left ventricle apical. What is your diagnosis?
- Assistant
Diagnosis: Loeffler Endocarditis (Eosinophilic Endomyocardial Disease) Secondary to Myeloid Hypereosinophilic Syndrome
Explanation:
The patient presents with signs and symptoms consistent with Loeffler endocarditis, a form of eosinophilic endomyocardial disease, which is often associated with hypereosinophilic syndrome (HES).
Key Clinical Features:
-
Persistent Hypereosinophilia:
- Eosinophil count of 8,710 cells/μL (normal < 400 cells/μL).
- Bone marrow biopsy showing proliferation of eosinophilic granulocytic myeloid line with immature forms, confirming myeloid hypereosinophilic syndrome.
-
Cardiac Involvement:
- Chest pain and elevated cardiac troponin levels (1.07 ng/mL; normal < 0.015 ng/mL), indicating myocardial injury.
- ECG abnormalities with diffuse T-wave inversion.
- Echocardiography and Cardiac MRI Findings:
- Apical myocardial hypertrophy and thickening, suggestive of endocardial fibrosis.
- Left ventricular apical obliteration by a large thrombus.
- Diffuse endocardial edema and hyperemia on MRI.
- Delayed gadolinium enhancement indicative of fibrosis.
- "V sign" on MRI: a three-layered appearance at the apex representing thrombus, fibrotic endocardium, and underlying myocardium.
-
Systemic Embolization:
- Brain MRI showing multiple small ischemic lesions in the cortical and subcortical regions of the frontal and occipital lobes.
- Symptoms of sudden blurred vision and headache, consistent with cerebral emboli from cardiac thrombus.
-
Exclusion of Other Causes:
- Negative tests for parasitic and infectious etiologies (e.g., Toxocara canis, filariasis, echinococcosis), which can cause secondary eosinophilia and cardiac involvement.
Pathophysiology:
- Loeffler Endocarditis is characterized by eosinophil-mediated damage to the endocardium and myocardium, leading to inflammation, necrosis, and fibrosis.
- The hypereosinophilia results in infiltration of eosinophils into cardiac tissues. Eosinophil degranulation releases cytotoxic proteins (e.g., major basic protein) that damage the endocardium.
- This damage promotes thrombus formation, particularly in the ventricular apex, and subsequent fibrosis, leading to restrictive cardiomyopathy.
- Embolic events occur due to dislodgement of thrombi, causing ischemic lesions in various organs, including the brain.
Management and Outcome:
- Initiation of corticosteroid therapy to reduce eosinophil count and inflammation.
- Chemotherapy with imatinib (STI-571) for myeloid hypereosinophilic syndrome, particularly effective if associated with tyrosine kinase mutations (e.g., FIP1L1-PDGFRA fusion gene).
- Anticoagulation with heparin to manage and prevent thrombus formation.
- Follow-up MRI showing improvement in cardiac findings correlates with clinical improvement.
Conclusion:
The constellation of persistent hypereosinophilia, cardiac involvement with endocardial fibrosis and thrombus formation, and systemic embolic phenomena strongly supports the diagnosis of Loeffler Endocarditis secondary to Myeloid Hypereosinophilic Syndrome.
-